Edition:
United States

Santhera Pharmaceuticals Holding AG (SANN.S)

SANN.S on Swiss Exchange

18.48CHF
23 May 2018
Change (% chg)

CHF0.12 (+0.65%)
Prev Close
CHF18.36
Open
CHF18.20
Day's High
CHF18.48
Day's Low
CHF18.00
Volume
7,192
Avg. Vol
45,298
52-wk High
CHF74.00
52-wk Low
CHF16.50

Select another date:

Thu, Apr 5 2018

BRIEF-Santhera Successfully Completes First Clinical Trial With Omigapil In Patients With Congenital Muscular Dystrophy ‍​

* SUCCESSFUL COMPLETION OF FIRST CLINICAL TRIAL WITH OMIGAPIL IN PATIENTS WITH CONGENITAL MUSCULAR DYSTROPHY ‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Santhera Pharmaceuticals FY ‍Net Result At CHF -51.5 Mln

* SANTHERA PHARMACEUTICALS - FY ‍NET REVENUES FROM SALES OF LEAD PRODUCT RAXONE® INCREASED BY 21% TO CHF 22.9 MILLION​

Santhera's Raxone shows no efficacy benefit in MS study

ZURICH Santhera Pharmaceuticals said on Monday a study of its medicine Raxone in primary progressive multiple sclerosis showed no difference between the treatment and placebo groups in disease progression, another setback for the Swiss drug company.

BRIEF-Santhera Pharmaceuticals ‍Reports Outcome Of Exploratory Trial With Idebenone In PPMS Conducted At NIH​

* ‍REPORTS OUTCOME OF EXPLORATORY TRIAL WITH IDEBENONE IN PPMS CONDUCTED AT NIH​

BRIEF-Santhera Completes Capital Increase To Settle Obtained License From Polyphor

* SANTHERA COMPLETES CAPITAL INCREASE TO SETTLE OBTAINED LICENSE FROM POLYPHOR

BRIEF-Santhera Says Obtains Worldwide Exclusive License From Polyphor

* SANTHERA OBTAINS WORLDWIDE EXCLUSIVE LICENSE FROM POLYPHOR TO DEVELOP AND COMMERCIALIZE CLINICAL STAGE CANDIDATE FOR CYSTIC FIBROSIS AND OTHER PULMONARY DISEASES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Santhera Launches U.S. Expanded Access Program With Idebenone For Patients With DMD

* SANTHERA LAUNCHES U.S. EXPANDED ACCESS PROGRAM WITH IDEBENONE FOR PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Santhera Pharmaceuticals Holding 2017 Revenues From Sales Of Raxone Up At CHF 22.9 Million

* INCREASE OF 21% YOY IN FY NET REVENUES TO CHF 22.9 MILLION (2016: CHF 19.0 MILLION) FROM SALES OF RAXONE

BRIEF-Santhera: Negative CHMP Opinion On Appeal For Authorization Of Raxone

* SANTHERA RECEIVES NEGATIVE CHMP OPINION ON APPEAL FOR AUTHORIZATION OF RAXONE® IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Shares In Santhera Pharmaceuticals Holding AG Suspended From Trading Until Further Notice‍​

Jan 24 Shares In Santhera Pharmaceuticals Holding Ag are suspended from trading until further notice - Six Swiss Exchange said.

Select another date: